Swine fever vaccine helps protect pigs against classical swine fever (CSF), also known as hog cholera, and African swine fever (ASF) viruses. CSF is a highly contagious viral disease of pigs characterized by fever, loss of appetite, weakness, and abortion. ASF is a severe hemorrhagic disease affecting domestic and wild pigs. It is not treatable or preventable with vaccines.wswThe global swine industry has faced billion-dollar losses due to outbreaks of CSF and ASF in recent years. Vaccination is considered one of the most effective measures for the control of CSF and ASF. Apart from direct losses due to mortality, outbreaks can severely disrupt international trade due to import restrictions imposed to contain the spread.
The global Swine Fever Vaccine Market is estimated to be valued at US$ 2885.25 Mn in 2023 and is expected to exhibit a CAGR of 5.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market key trends:
One of the key trends in the swine fever vaccine market is the development and commercialization of marker vaccines. Marker vaccines are genetically altered versions of the live virus vaccines that allow differentiation between infected and vaccinated animals. They help contain outbreaks more effectively by allowing differentiation and targeted culling. For instance, in 2021, Ceva Animal Health obtained marketing authorization from the European Commission for its new marker CSF vaccine Suvaxyn CSF Marker. This second-generation vaccine uses a conventional adjuvant and a genetically modified live virus that can differentiate infected animals from vaccinated ones. Such advances are expected to boost the adoption of swine fever vaccination programs globally.
Threat of new entrants: The threat of new entrants is moderate as developing an effective vaccine requires significant R&D investment and government approval. However, increasing prevalence of swine fever provides opportunities for new players.
Bargaining power of buyers: The bargaining power of buyers is moderate to high. Buyers can negotiate prices as there are several players offering swine fever vaccines. However, severity of swine fever outbreaks makes buyers dependent on vaccine suppliers.
Bargaining power of suppliers: The bargaining power of suppliers is low to moderate. Key raw materials for vaccine production such as inactivated viruses are available from multiple sources at competitive costs. However, supplier integration is important considering technical requirements.
Threat of new substitutes: There is negligible threat of substitute products as vaccination remains the primary preventive measure for swine fever. While alternatives such as improved biosecurity provides synergies, no direct substitute exists.
Competitive rivalry: The market has moderate competition owing to presence of multiple regional and global players. Key players compete based on product efficacy, pricing and portfolio expansion into new geographies.
The Global Swine Fever Vaccine Market Trend is expected to witness high growth over the forecast period driven by rising prevalence of the disease across major pork producing regions.
Regional analysis: Asia Pacific is projected to dominate the market during the forecast period. This is mainly attributed to the growing outbreaks of swine fever in key pork producing countries like China and India. Additionally, increasing vaccination adoption in countries like Vietnam, Indonesia and Thailand will further aid regional growth.
Key players: Key players operating in the swine fever vaccine market include Merck & Co., Inc. (Merck Animal Health), Ceva, Zoetis Services LLC, Boehringer Ingelheim International GmbH, Indian Immunologicals Ltd., Bioveta, a.s., Komipharm, and EC21 Inc. The market is competitive in nature with players focusing on new vaccine launches, production expansion and partnerships with local players in strategic regions.
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it